2 Min Read
** Medical tool maker's shares up 20 pct at $1.00; stock one of the top gainers on the Nasdaq
** Martin Shkreli, the controversial CEO of Turing Pharmaceuticals Inc, called WaferGen an "okay investment for sure," as he reviewed the company's financial reports on a livestream meeting with retail investors (bit.ly/1IvvLow)
** Shkreli also called cancer drug developers Aeterna Zentaris Inc and Cyclacel Pharmaceuticals Inc "pretty terrible" and "worthless"
** Aeterna Zentaris Inc's shares down 14 pct at $9.51; Cyclacel Pharmaceuticals Inc down 22 pct at $0.79
** Shkreli said Aeterna's late-stage experimental cancer drug for endometrial cancer is likely to fail noting that targeted forms of cancer drugs "don't work better than the original drug," adding he was "just guessing" on study failure
** Former hedge fund manager Timothy Sykes put both cancer drug developers on Sunday on a list of stocks that he expected to be shorted on Monday
** Up to Friday's close, WaferGen stock had lost 72 pct of its value this year, Aeterna stock had fallen about 82 pct; Cyclacel stock had risen about 46 percent